PNK 007

Drug Profile

PNK 007

Alternative Names: Cord-blood-derived-natural-killer-cells-Celgene; PNK007

Latest Information Update: 16 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celgene Corporation
  • Developer Celgene Corporation; Celularity
  • Class Cell therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Multiple myeloma
  • Preclinical Glioblastoma

Most Recent Events

  • 01 Mar 2018 Celgene terminates a phase I trial in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA due to business reasons (NCT02781467)
  • 21 Feb 2018 Celularity announces intention to submit IND to US FDA for Glioblastoma in 2H 2018
  • 01 Jan 2017 Celgene initiates enrolment in a phase I trial for Multiple myeloma (Newly-diagnosed, Second-line herapy or greater) in USA (NCT02955550)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top